Skip to main content
. 2012 Jun 26;83(1):21–29. doi: 10.4174/jkss.2012.83.1.21

Fig. 2.

Fig. 2

Caspase-3 activities were analyzed by Western blot analysis. SW480 cells (A) and DLD-1 cells (B) were treated with FOLFOX (FX), FOLFOX + bevacizumab (FXB), FOLFOX + cetuximab (FXC), FOLFIRI (FR), FOLFIRI + bevacizumab (FRB), or FOLFIRI + cetuximab (FRC) for 48 hours. Harvested-cell lysates were analyzed by Western blotting with an anti-caspase-3 antibody. C, control; FOLFOX (FX), 5-fluorouracil (5-FU) + leucovorin + oxaliplatin; FOLFIRI (FR), 5-FU + leucovorin + irinotecan.